drugset / Trial / NCT01011686

Safety Study of Autologous Cultured Adipose -Derived Stem Cells for the Fecal Incontinence

NCT01011686 ↗

Phase 1 Terminated Anterogen Co., Ltd.

Summary

Fecal incontinence affects 18.4% adults in the community and greatly impacts quality of life. There's a problem like inconvenience, pain or allergic response in many therapeutic methods such as a surgical operation or material injection. ANT-SM is autologous adipose-derived stem cell, and so, expect of no immune responses. In this study, patients are given injection of ANT-AM in anal sphincter and followed for 4 weeks to test the safety.

Timeline

Start
—
Primary completion
—
Completion
—

Outcome

Outcome not reported

Stopped (Enrollment): “Few subject enrolled”

Drugs

EvaluationDrugModalityDoseRoute
Subject ANT-SM Cell therapy — Other

Indications

No indication recorded.